Financial Results (Standalone)

The Board approved the Un-Audited Standalone Financial Results for the quarter ended June 30, 2026 (Q1 FY27):

  • Revenue from operations: ₹9,827.58 lakh (₹98.28 crore)
  • Other income: ₹44.34 lakh
  • Total income: ₹9,871.92 lakh
  • Profit before exceptional items and tax: ₹779.34 lakh
  • Exceptional items: Nil (compared to a loss of ₹12,100.64 lakh in Q1 FY26)
  • Profit before tax: ₹779.34 lakh
  • Tax expense: ₹128.68 lakh (Current tax: ₹212.64 lakh, Deferred tax credit: ₹83.96 lakh)
  • Profit for the period: ₹650.67 lakh (₹6.51 crore)
  • Other comprehensive income: ₹7.81 lakh
  • Total comprehensive income for the period: ₹658.48 lakh
  • Earnings per share (Basic & Diluted): ₹0.17
  • Paid-up equity share capital: ₹3,821.17 lakh (Face value ₹1 each)

Financial Results (Consolidated)

The Board also approved the Un-Audited Consolidated Financial Results for the quarter ended June 30, 2026:

  • Revenue from operations: ₹12,127.38 lakh (₹121.27 crore)
  • Other income: ₹100.29 lakh
  • Total income: ₹12,227.67 lakh
  • Profit before exceptional items and tax: ₹1,008.97 lakh
  • Exceptional items: Nil
  • Profit before tax: ₹1,008.97 lakh
  • Tax expense: ₹194.50 lakh (Current tax: ₹256.56 lakh, Deferred tax credit: ₹62.06 lakh)
  • Profit for the period: ₹814.47 lakh
  • Profit attributable to shareholders of the company: ₹675.94 lakh (₹6.76 crore)
  • Profit attributable to non-controlling interest: ₹138.53 lakh
  • Other comprehensive income: ₹190.34 lakh
  • Total comprehensive income for the period: ₹1,004.81 lakh
  • Earnings per share (Basic & Diluted): ₹0.18

Lapse and Forfeiture of Convertible Warrants

The Board considered and approved the lapse and forfeiture of 3,50,57,990 convertible warrants issued under SEBI (ICDR) Regulations, 2018. The warrant holders did not exercise the conversion option within 18 months from the date of allotment (February 09, 2025). The amount received on these warrants, totaling ₹22,87,53,813 (₹22.88 crore), stands forfeited as per Regulation 169(3) of SEBI (ICDR) Regulations, 2018.

Details of Lapsed Warrants:

  • Type of securities: Convertible Warrants
  • Type of issuance: Preferential Allotment
  • Total warrants originally allotted: 10,97,50,000 (post split)
  • Issue price per warrant: ₹26.1 (post split)
  • Date of allotment: August 10, 2023
  • Tenure: 18 months
  • Number of warrants exercised: Nil
  • Number of warrants lapsed: 3,50,57,990
  • Amount forfeited: ₹22,87,53,813
  • Change in capital structure: Nil

Warrant Holders and Amounts Forfeited:

1. Swati Sinha: 90,00,000 warrants; ₹5,87,25,000 forfeited

2. Amit Raj Sinha (HUF): 1,00,00,000 warrants; ₹6,52,50,000 forfeited

3. Karan Raj Sinha: 50,00,000 warrants; ₹3,26,25,000 forfeited

4. Saloni Sinha: 50,00,000 warrants; ₹3,26,25,000 forfeited

5. Tano Investments Opportunities Fund: 58,30,000 warrants; ₹3,80,40,750 forfeited

6. Kamma Sesha Sai Chaitanya: 1,37,300 warrants; ₹8,96,031 forfeited

7. Bharathi Yeguvandla: 30,020 warrants; ₹1,96,045 forfeited

8. Raghu Vemulapalli: 60,670 warrants; ₹3,95,987 forfeited

Director Appointments

1. Mr. Chidambarnathan: Retires by rotation and being eligible, offered himself for re-appointment in the ensuing annual general meeting.

2. Ms. Dhanalakshmi Guntaka (DIN: 09363100): Based on the recommendation of the Nomination and Remuneration Committee, the Board approved her re-appointment as an Independent Director for a second term of five years, effective from October 18, 2026, to October 17, 2031, subject to shareholder approval.

  • Profile: Approximately 48 years old, holds Master's and bachelor's degrees in Commerce. Fellow member of the Institute of Chartered Accountants of India. Founding partner of D A Y & Associates, Chartered Accountants. Not related to any director of the company and not debarred from holding office.

3. Mr. Janardhana Reddy Yeddula (DIN: 03207357): Based on the recommendation of the Nomination and Remuneration Committee, the Board approved his re-appointment as an Independent Director for a second term of five years, effective from November 30, 2026, to November 29, 2031, subject to shareholder approval.

  • Profile: A qualified cost accountant (FCMA) from the Institute of Cost Accountants of India. Completed B.Com from Sri Venkateswara University, Tirupati. Over 40 years of experience in finance leadership across bulk drugs, formulations, energy conductors, cement, fertilizers, agro chemicals, real estate, and infrastructure. Not related to any director of the company and not debarred from holding office.

IPO Proceeds Utilization

The utilization of Net IPO Proceeds as of June 30, 2026, is summarized below:

  • For expansion of production capacity for MCC at existing facility at Dahej, Gujarat: ₹2,815.82 lakh (Fully utilized by Q4 FY23)
  • For expansion of production capacity for MCC at existing facility at Jhagadia, Gujarat: ₹2,924.13 lakh
  • To establish a CCS project at Dahej, Gujarat: ₹3,229.87 lakh (Unutilized amount: ₹3,229.87 lakh)
  • Total: ₹8,969.82 lakh

Segment Information (Standalone)

For the quarter ended June 30, 2026:

  • Pharmaceuticals segment revenue: ₹8,521.61 lakh
  • Operational and Management segment revenue: ₹1,305.97 lakh
  • Total revenue: ₹9,827.58 lakh
  • Segment results: Profit before tax and interest was ₹997.96 lakh (Pharmaceuticals: ₹769.35 lakh, Operational and Management: ₹228.61 lakh)

Segment Information (Consolidated)

For the quarter ended June 30, 2026:

  • Pharmaceuticals segment revenue: ₹10,821.40 lakh
  • Operational and Management segment revenue: ₹1,305.97 lakh
  • Total revenue: ₹12,127.38 lakh
  • Segment results: Profit before tax and interest was ₹1,310.28 lakh (Pharmaceuticals: ₹1,081.67 lakh, Operational and Management: ₹228.61 lakh)

Subsidiaries

The consolidated results include the following subsidiary entities:

1. Sigachi US INC

2. Sigachi MENA FZCO

3. Trimax Bio Sciences Private Limited

Auditor Review

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors. The limited review was conducted by Yelamanchi & Associates, Chartered Accountants (Firm Registration No. 000041S), who issued an unmodified review conclusion.

Meeting Details

The Board meeting was held on August 13, 2026, at 12:00 Noon through Video Conference and concluded at 04:00 PM.